stockrow
Friday 6 November 2026
Export PSNL’s income statement to Excel — free account
Personalis, Inc.
PSNL Healthcare Diagnostics & Research
Personalis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.6 million, down 17.7% from fiscal 2024.
- Revenue
- +76.6%
- EPS
- −33.3%
- Free cash flow
- −15.5%
Quarter to September 2026, against a year earlier
15.81
0.26
+1.67%
Follow PSNL
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| (62.14%) | (50.32%) | (41.35%) | (35.02%) | ||
| (44.66%) | (37.55%) | (31.92%) | (26.89%) | ||
ROIC |
(358.37%) | (317.48%) | (297.38%) | (259.21%) | |
Return on Tangible Assets |
(53.25%) | (43.35%) | (35.71%) | (29.75%) | |
Average Days of Receivables |
81.50 | 79.12 | 73.67 | 84.91 | |
Free Cash Flow per Share |
(0.91) | (0.96) | (0.81) | (0.89) | |
Free Cash Flow |
(97.57) | (100.85) | (84.53) | (79.45) | |
Capital Expenditures |
— | (8.56) | (5.06) | (4.50) | |
| Other line items | |||||
Cash ROIC |
(24.19%) | (22.52%) | (17.32%) | (15.85%) | |
Accounts Receivable Turnover |
4.98 | 5.56 | 5.38 | 5.72 | |
Accounts Payable Turnover |
5.25 | 4.69 | 5.41 | 5.56 | |
Inventory Turnover |
11.18 | 8.07 | 9.39 | 8.92 | |
Average Days of Payables |
78.60 | 96.03 | 83.12 | 88.01 | |
Days of Inventory on Hand |
40.06 | 57.83 | 45.44 | 41.63 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
74.31% | 80.55% | 80.85% | 72.17% | |
Selling, General and Administrative Expense of Revenue |
99.06% | 96.21% | 91.78% | 76.92% | |
Share Based Compensation of Revenue |
15.78% | 15.67% | 15.13% | 13.54% | |
Interest Coverage |
(683.98) | (536.66) | (457.69) | (429.55) | |
Operating CF/Net income |
0.82 | 0.86 | 0.83 | 0.92 | |
Depreciation/Fixed assets |
0.00 | 0.12 | 0.12 | 0.14 | |
Capex/Depreciation |
— | (1.49) | (0.87) | (0.74) | |
Revenue per Share |
0.75 | 0.66 | 0.62 | 0.78 | |
Operating CF per Share |
(0.91) | (0.88) | (0.76) | (0.84) | |
Capex per Share |
0.00 | (0.08) | (0.05) | (0.05) | |
Capex to Sales |
0.00 | 0.12 | 0.08 | 0.06 |
Columns are period end dates · fundamentals updated 4 Nov 2026